Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 141Lung Neoplasms 51Pancreatic Neoplasms 30Non-Squamous Non-Small Cell Lung Cancer 18Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Glioblastoma 13Gliosarcoma 12Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Adenocarcinoma, Bronchiolo-Alveolar 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Squamous Cell 7Carcinoma, Renal Cell 7Astrocytoma 6Oligodendroglioma 5Carcinoma 5Urinary Bladder Neoplasms 4Liver Neoplasms 4Glioma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Paclitaxel 2Carboplatin 2Bevacizumab 2Taxes 1Radiotherapy 1Nivolumab 1Immunoglobulin G 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Clear Cell × Erlotinib Hydrochloride × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡